Black Triangle Warning Dropped From Pfizer's Smoking Cessation Drug Label
Executive Summary
Europe has removed its black triangle warning from the label of Pfizer Inc.'s smoking cessation drug Champix (varenicline; known as Chantix in the US) on the back of new long-term use data.
You may also be interested in...
US FDA orders "black box" suicidality warnings and studies for Chantix and Zyban
The US FDA has ordered Pfizer and GlaxoSmithKline to add "black box" label warnings about serious neuropsychiatric effects for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The companies also must conduct postmarketing clinical trials to determine the incidence of serious neuropsychiatric symptoms, including depression and suicidality, in patients taking the therapies.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.